{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:05:05Z","timestamp":1776197105810,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016206","name":"Clinical and Translational Science Institute, University of California, Los Angeles","doi-asserted-by":"publisher","award":["5KL2TR001882-08"],"award-info":[{"award-number":["5KL2TR001882-08"]}],"id":[{"id":"10.13039\/100016206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hfc.2025.11.005","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:24:20Z","timestamp":1774484660000},"page":"243-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving Strategies in Cardiac Amyloidosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Ashley F.","family":"Stein-Merlob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Swier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darko","family":"Vucicevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10038","key":"10.1016\/j.hfc.2025.11.005_bib1","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.hfc.2025.11.005_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib3","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Failure"},{"issue":"6","key":"10.1016\/j.hfc.2025.11.005_bib4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3390\/jcm12062273","article-title":"Estimating the prevalence of cardiac amyloidosis in old patients with heart failure\u2014barriers and opportunities for improvement: the PREVAMIC study","volume":"12","author":"Ruiz-Hueso","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib5","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"10.1016\/j.hfc.2025.11.005_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/cer-2017-0100","article-title":"Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data","volume":"7","author":"Quock","year":"2018","journal-title":"Journal of Comparative Effectiveness Research"},{"issue":"10","key":"10.1016\/j.hfc.2025.11.005_bib7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"37","key":"10.1016\/j.hfc.2025.11.005_bib9","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangione","year":"2018","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib10","first-page":"488","article-title":"ATTR amyloidosis: current and emerging management strategies","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC (J Am Coll Cardiol)"},{"issue":"10","key":"10.1016\/j.hfc.2025.11.005_bib11","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1529\/biophysj.106.098608","article-title":"A three-stage kinetic model of amyloid fibrillation","volume":"92","author":"Lee","year":"2007","journal-title":"Biophys J"},{"issue":"40","key":"10.1016\/j.hfc.2025.11.005_bib12","doi-asserted-by":"crossref","first-page":"13530","DOI":"10.1039\/D1SC03190B","article-title":"A generic approach to decipher the mechanistic pathway of heterogeneous protein aggregation kinetics","volume":"12","author":"Tikader","year":"2021","journal-title":"Chem Sci"},{"issue":"27","key":"10.1016\/j.hfc.2025.11.005_bib13","doi-asserted-by":"crossref","first-page":"E6201","DOI":"10.1073\/pnas.1807024115","article-title":"Kinetic analysis of the multistep aggregation pathway of human transthyretin","volume":"115","author":"Sun","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"10.1016\/j.hfc.2025.11.005_bib14","doi-asserted-by":"crossref","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","article-title":"Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.hfc.2025.11.005_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nnano.2011.102","article-title":"Nanomechanics of functional and pathological amyloid materials","volume":"6","author":"Knowles","year":"2011","journal-title":"Nat Nanotechnol"},{"issue":"27","key":"10.1016\/j.hfc.2025.11.005_bib16","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1073\/pnas.1309690110","article-title":"Exceptional rigidity and biomechanics of amyloid revealed by 4D electron microscopy","volume":"110","author":"Fitzpatrick","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"10.1016\/j.hfc.2025.11.005_bib17","doi-asserted-by":"crossref","first-page":"295701","DOI":"10.1088\/1361-6528\/aabd8a","article-title":"Correlation between the hierarchical structures and nanomechanical properties of amyloid fibrils","volume":"29","author":"Lee","year":"2018","journal-title":"Nanotechnology"},{"issue":"2","key":"10.1016\/j.hfc.2025.11.005_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","article-title":"Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology","volume":"206","author":"Bergstr\u00f6m","year":"2005","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/path.2618","article-title":"Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy","volume":"219","author":"Misumi","year":"2009","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-biochem-060614-033955","article-title":"The biology of proteostasis in aging and disease","volume":"84","author":"Labbadia","year":"2015","journal-title":"Annu Rev Biochem"},{"issue":"18","key":"10.1016\/j.hfc.2025.11.005_bib21","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.febslet.2012.07.029","article-title":"Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin","volume":"586","author":"Almeida","year":"2012","journal-title":"FEBS (Fed Eur Biochem Soc) Lett"},{"issue":"12","key":"10.1016\/j.hfc.2025.11.005_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/NEN.0b013e31823a44f4","article-title":"Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy","volume":"70","author":"Magalh\u00e3es","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"10.1016\/j.hfc.2025.11.005_bib23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib24","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.hfc.2025.11.005_bib26","first-page":"1076","article-title":"ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the american college of cardiology solution set oversight committee","volume":"81","author":"Writing","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jjcc.2024.03.008","article-title":"Atrial fibrillation in the setting of cardiac amyloidosis - a review of the literature","volume":"84","author":"Bazoukis","year":"2024","journal-title":"J Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2025.11.005_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2025.11.005_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2022.04.045","article-title":"Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis","volume":"358","author":"Dale","year":"2022","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2025.11.005_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10741-023-10350-1","article-title":"Valvular heart disease in patients with cardiac amyloidosis","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.hfc.2025.11.005_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaccao.2021.08.008","article-title":"Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly indian population: a pilot study","volume":"3","author":"Singal","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.hfc.2025.11.005_bib36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jcin.2012.03.012","article-title":"Pathology of transcatheter valve therapy","volume":"5","author":"Nietlispach","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"6","key":"10.1016\/j.hfc.2025.11.005_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-125-6-199609150-00009","article-title":"Resolution of heart failure in patients with AL amyloidosis","volume":"125","author":"Dubrey","year":"1996","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.hfc.2025.11.005_bib39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2025.11.005_bib40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0039-1688994","article-title":"Neuropathy associated with systemic amyloidosis","volume":"39","author":"Kaku","year":"2019","journal-title":"Semin Neurol"},{"key":"10.1016\/j.hfc.2025.11.005_bib41","article-title":"Cardiac amyloidosis: epidemiology, diagnosis and therapy. ESC heart fail","volume":"19","author":"Farmakis","year":"2021","journal-title":"European Society of Cardiology e-Journal of Cardiology Practice"},{"issue":"22","key":"10.1016\/j.hfc.2025.11.005_bib42","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2025.11.005_bib43","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/heartjnl-2019-316215","article-title":"Global longitudinal strain: clinical use and prognostic implications in contemporary practice","volume":"106","author":"Abou","year":"2020","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ehf2.13738","article-title":"Echocardiographic and clinical predictors of cardiac amyloidosis: limitations of apical sparing","volume":"9","author":"Kyrouac","year":"2022","journal-title":"ESC Heart Failure"},{"issue":"7","key":"10.1016\/j.hfc.2025.11.005_bib45","first-page":"1174","article-title":"Relative left ventricular apical sparing of longitudinal strain in cardiac amyloidosis","volume":"12","author":"Rapezzi","year":"2019","journal-title":"JACC (J Am Coll Cardiol)"},{"issue":"7","key":"10.1016\/j.hfc.2025.11.005_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41569-020-0334-7","article-title":"Diagnostic imaging of cardiac amyloidosis","volume":"17","author":"Martinez-Naharro","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hfc.2025.11.005_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/jimaging9020048","article-title":"Developing an echocardiography-based, automatic deep learning framework for the differentiation of increased left ventricular wall thickness etiologies","volume":"9","author":"Li","year":"2023","journal-title":"J Imag"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcmg.2023.09.011","article-title":"Echocardiography-based deep learning model to differentiate constrictive pericarditis and restrictive cardiomyopathy","volume":"17","author":"Chao","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning","volume":"7","author":"Duffy","year":"2022","journal-title":"JAMA Cardiology"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib51","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008225","article-title":"Avoiding catastrophe","volume":"14","author":"Witteles","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.hfc.2025.11.005_bib52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib53","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.hfc.2025.11.005_bib54","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur Heart J Cardiovasc Imag"},{"issue":"5","key":"10.1016\/j.hfc.2025.11.005_bib55","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0002-9149(83)80140-4","article-title":"Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis","volume":"51","author":"Falk","year":"1983","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.hfc.2025.11.005_bib56","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2025.11.005_bib57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2967\/jnmt.123.265568","article-title":"Novel tracers for the imaging of cardiac amyloidosis","volume":"51","author":"Shetty","year":"2023","journal-title":"J Nucl Med Technol"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib58","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC202303210","article-title":"Cardiac amyloidosis","volume":"176","author":"Bloom","year":"2023","journal-title":"Ann Intern Med"},{"issue":"8853","key":"10.1016\/j.hfc.2025.11.005_bib59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13506120701614032","article-title":"Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation","volume":"14","author":"Liepnieks","year":"2007","journal-title":"Amyloid"},{"issue":"9","key":"10.1016\/j.hfc.2025.11.005_bib61","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.hfc.2025.11.005_bib64","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hfc.2025.11.005_bib66","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hfc.2025.11.005_bib69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib71","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci Res"},{"issue":"2","key":"10.1016\/j.hfc.2025.11.005_bib72","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/bi5011249","article-title":"Cooperative stabilization of transthyretin by clusterin and diflunisal","volume":"54","author":"Greene","year":"2015","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.hfc.2025.11.005_bib73","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Heart Fail"},{"issue":"24","key":"10.1016\/j.hfc.2025.11.005_bib74","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"5539","key":"10.1016\/j.hfc.2025.11.005_bib75","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans -suppression of misfolding in an amyloid disease","volume":"293","author":"HammarstroM","year":"2001","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib76","first-page":"519","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy","volume":"8","author":"Maurer","year":"2015","journal-title":"Circulation: Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib77","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circulation: Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2025.11.005_bib78","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","article-title":"Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy","volume":"33","author":"Hornstrup","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"17","key":"10.1016\/j.hfc.2025.11.005_bib79","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.hfc.2025.11.005_bib80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined Doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"issue":"sup1","key":"10.1016\/j.hfc.2025.11.005_bib82","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","author":"Wixner","year":"2017","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis","volume":"25","author":"Karlstedt","year":"2019","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib85","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"10.1016\/j.hfc.2025.11.005_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.1767","article-title":"NNC6019\u20130001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial","volume":"43","author":"Fontana","year":"2022","journal-title":"Eur Heart J"},{"issue":"Supplement_2","key":"10.1016\/j.hfc.2025.11.005_bib88","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.3300","article-title":"Characterization of AT-02, a pan-amyloid-binding peptide fusion immunoglobulin with high binding potency, complement activation, and immune cell stimulation","volume":"44","author":"Wall","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2025.11.005_bib89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/OP.22.00396","article-title":"Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation","volume":"19","author":"Dima","year":"2023","journal-title":"JCO Oncology Practice"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2025.11.005_bib91","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib92","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2005-08-3253","article-title":"Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis","volume":"107","author":"Gillmore","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hfc.2025.11.005_bib93","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1111\/ajt.15487","article-title":"Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis","volume":"19","author":"Trachtenberg","year":"2019","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.hfc.2025.11.005_bib94","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/TP.0b013e3181f10edb","article-title":"Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure","volume":"90","author":"Dey","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.hfc.2025.11.005_bib95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14797\/mdcj-8-3-8","article-title":"Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management","volume":"8","author":"Estep","year":"2012","journal-title":"Methodist DeBakey Cardiovascular Journal"},{"issue":"5","key":"10.1016\/j.hfc.2025.11.005_bib96","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s10741-021-10209-3","article-title":"State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond","volume":"27","author":"Kumar","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"Supplement 1","key":"10.1016\/j.hfc.2025.11.005_bib97","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/blood-2023-186373","article-title":"Cael-101 Enhances the clearance of light chain fibrils and intermediate aggregates by phagocytosis","volume":"142","author":"Costello","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hfc.2025.11.005_bib98","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0735-1097(22)01296-7","article-title":"Safety and tolerability of cael-101, an anti-amyloid monoclonal antibody, in combination with plasma cell dyscrasia therapy in patients with light-chain amyloidosis: results from a phase 2 study","volume":"79","author":"Valent","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.hfc.2025.11.005_bib99","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hfc.2025.11.005_bib100","doi-asserted-by":"crossref","first-page":"TPS8076","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8076","article-title":"Birtamimab in patients with Mayo stage IV AL amyloidosis: rationale for confirmatory affirm-AL phase 3 study","volume":"40","author":"Gertz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hfc.2025.11.005_bib101","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiology"},{"issue":"6","key":"10.1016\/j.hfc.2025.11.005_bib102","doi-asserted-by":"crossref","DOI":"10.1007\/s12170-021-00670-y","article-title":"Racial and ethnic disparities in transthyretin cardiac amyloidosis","volume":"15","author":"Spencer-Bonilla","year":"2021","journal-title":"Current Cardiovascular Risk Reports"},{"issue":"8","key":"10.1016\/j.hfc.2025.11.005_bib103","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028534","article-title":"Design and Rationale the SCAN-MP (Screening for cardiac amyloidosis with nuclear imaging in minority populations) study","volume":"12","author":"Ruberg","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","article-title":"Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges","volume":"26","author":"Bruno","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"11","key":"10.1016\/j.hfc.2025.11.005_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00385-0","article-title":"Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities","volume":"10","author":"Staron","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.hfc.2025.11.005_bib106","article-title":"Orphan drug development in cardiovascular medicine","volume":"13","author":"Khan","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.hfc.2025.11.005_bib107","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2025.11.005_bib108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.hfc.2025.11.005_bib109","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625001072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625001072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:11:43Z","timestamp":1776193903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713625001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1551713625001072"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2025.11.005","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Strategies in Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}